The stability of hexacosanoyl lysophosphatidylcholine in dried-blood spot quality control materials for X-linked adrenoleukodystrophy newborn screening

Clinical Biochemistry

Volumn 48, Issue 1-2, 2015, Pages 8-10

  Haynes, Christopher A ^a   De Jesús, Víctor R ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Dried blood spot; Lysophosphatidylcholine; Newborn screening; Tandem mass spectrometry; X linked adrenoleukodystrophy

Indexed keywords

DESICCANT; HEXACOSANOYL LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ADRENOLEUKODYSTROPHY; ARTICLE; CONCENTRATION (PARAMETERS); DRIED BLOOD SPOT TESTING; ELECTROSPRAY MASS SPECTROMETRY; ENVIRONMENTAL TEMPERATURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMIDITY; NEWBORN SCREENING; PROTEIN STABILITY; QUALITY CONTROL; STORAGE TEMPERATURE; TANDEM MASS SPECTROMETRY; X CHROMOSOME LINKED DISORDER; BLOOD; HUMAN; NEWBORN; PROCEDURES;

ADRENOLEUKODYSTROPHY; DRIED BLOOD SPOT TESTING; HUMANS; INFANT, NEWBORN; LYSOPHOSPHATIDYLCHOLINES; NEONATAL SCREENING; QUALITY CONTROL;

EID: 84920287496     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.10.001     Document Type: Article

References (11)

1. Bezman L., Moser A.B., Raymond G.V., Rinaldo P., Watkins P.A., Smith K.D., et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001, 49:512-517.
2. Kemp S., Theodoulou F.L., Wanders R.J. Mammalian peroxisomal abc transporters: from endogenous substrates to pathology and clinical significance. Br J Pharmacol 2011, 164:1753-1766.
3. Hubbard W.C., Moser A.B., Liu A.C., Jones R.O., Steinberg S.J., Lorey F., et al. Newborn screening for x-linked adrenoleukodystrophy (x-ald): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 2009, 97:212-220.
4. Mei J.V., Alexander J.R., Adam B.W., Hannon W.H. Use of filter paper for the collection and analysis of human whole blood specimens. J Nutr 2001, 131:1631S-1636S.
5. Slazyk W.E., Hannon W.H. Quality assurance in the newborn screening laboratory. Laboratory methods for neonatal screening 1993, American Public Health Association, Washington DC. B.L. Therrell (Ed.).
6. Chace D.H., Adam B.W., Smith S.J., Alexander J.R., Hillman S.L., Hannon W.H. Validation of accuracy-based amino acid reference materials in dried-blood spots by tandem mass spectrometry for newborn screening assays. Clin Chem 1999, 45:1269-1277.
7. Haynes C.A., De Jesus V.R. Improved analysis of c26:0-lysophosphatidylcholine in dried-blood spots via negative ion mode HPLC-ESI-MS/MS for x-linked adrenoleukodystrophy newborn screening. Clin Chim Acta 2012, 413:1217-1221.
8. Chace D.H., Lim T., Hansen C.R., Adam B.W., Hannon W.H. Quantification of malonylcarnitine in dried blood spots by use of MS/MS varies by stable isotope internal standard composition. Clin Chim Acta 2009, 402:14-18.
9. Chace D.H., Spitzer A.R. Altered metabolism and newborn screening using tandem mass spectrometry: lessons learned from the bench to bedside. Curr Pharm Biotechnol 2011, 12:965-975.
10. De Jesus V.R., Chace D.H., Lim T.H., Mei J.V., Hannon W.H. Comparison of amino acids and acylcarnitines assay methods used in newborn screening assays by tandem mass spectrometry. Clin Chim Acta 2010, 411:684-689.
11. CLSI Blood collection on filter paper for newborn screening programs; approved standard 2013, CLSI publication, Wayne, PA, [NBS01-A6]. Sixth ed.